

February 12, 2024

Michael Henderson, M.D.  
Chief Executive Officer  
Apogee Therapeutics, Inc.  
221 Crescent St., Building 17, Suite 102b  
Waltham, MA 02453

Therapeutics, Inc.  
Statement on Form S-1  
9, 2024

Re: Apogee  
Draft Registration  
Submitted February  
CIK No. 0001974640

Dear Michael Henderson:

This is to advise you  
that we do not intend to review your registration statement.

We request that you publicly file your registration statement no  
later than 48 hours prior  
to the requested effective date and time. Please refer to Rules 460 and  
461 regarding requests for  
acceleration. We remind you that the company and its management are  
responsible for the  
accuracy and adequacy of their disclosures, notwithstanding any review,  
comments, action or  
absence of action by the staff.

Please contact Chris  
Edwards at 202-551-6761 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Melanie E. Neary